
SPECT Imaging Agent Gets Expanded FDA Approval for Patients with Suspected Dementia with Lewy Bodies
GE Healthcare’s DaTscan is reportedly the first radiopharmaceutical tracer agent approved by the Food and Drug Administration (FDA) for use in patients with suspected dementia with Lewy bodies.































